medigraphic.com
ISSN 1527-3172 (Digital)

2022, Número 1

<< Anterior Siguiente >>

MEDICC Review 2022; 24 (1)


Thrombotic microangiopathy in patients recovering from COVID-19

López-Marín L, Bacallao-Méndez RA, Llerena-Ferrer B, Badell-Moore A, García-Villar Y, Rodríguez-Leyva L, Herrera-Valdés R

Idioma: Ingles.
Referencias bibliográficas: 15
Paginas: 32-35
Archivo PDF: 241.71 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, etal. Clinical features of patients infected with 2019novel coronavirus in Wuhan, China. Lancet. 2020Feb 15;395(10223):497–506.

  2. Iba T, Levy JH, Connors JM, Warkentin TE,Thachil J, Levi M. The unique characteristics ofCOVID-19 coagulopathy. Crit Care. 2020 Jun18;24(1):360.

  3. Gavriilaki E, Brodsky RA. Severe COVID-19infection and thrombotic microangiopathy: successdoes not come easily. Br J Haematol. 2020Jun;189(6):e227−e230. Available at: https://doi.org/10.1111/bjh.16783

  4. Boudhabhay I, Rabant M, Coupry LM, MarchalA, Roumenina LT, El-Karoui K, et al. Case report:Adult post COVID-19 multisystem infl ammatorysyndrome and thrombotic microangiopathy.Research Square [Preprint]. 2020 Sep 16[cited 2021 Sep 18]. Available at: https://doi.org/10.21203/rs.3.rs-76310/v1

  5. Gabarre P, Dumas G, Dupont T, Darmon M,Azoulay E, Zafrani L. Acute kidney injury in criticallyill patients with COVID-19. Intensive CareMed. 2020 Jul;46(7):1339–48.

  6. Jhaveri KD, Meir LR, Flores Chang BS, Parikh R,Wanchoo R, Barilla-LaBarca ML, et al. Thromboticmicroangiopathy in a patient with COVID-19.Kidney Int. 2020 Aug;98(2):509–12.

  7. Falter T, Rossmann H, Menge P, Goetje J, GroenwoldtS, Weinmann A, et al. No evidence for classicthrombotic microangiopathy in COVID-19. JClin Med. 2021 Feb 9;10(4):671.

  8. Cervera R, Asherson RA. Antiphospholipid syndromeassociated with infections: clinical andmicrobiological characteristics. Immunobiology.2005;210(10):735–41.

  9. Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinfl ammatoryand autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020 Nov;114:102506. Availableat: https://doi.org/10.1016/j.jaut.2020.102506.Epub 2020 Jun 16.

  10. Chaturvedi S, Braunstein EM, Yuan X, Yu J,Alexander A, Chen H, et al. Complement activityand complement regulatory gene mutations areassociated with thrombosis in APS and CAPS.Blood. 2020 Jan 23;135(4):239–51.

  11. Bendapudi PK, Hurwitz S, Fry A, Marques MB,Waldo SW, Li A, et al. Derivation and externalvalidation of the PLASMIC score for rapidassessment of adults with thrombotic microangiopathies:a cohort study. Lancet Haematol [Internet].2017 Apr [cited 2021 Sep 18];4(4):e157–e64.Available at: http://dx.doi.org/10.1016/S2352-3026(17)30026-1

  12. Jokiranta TS. HUS and atypical HUS. Blood.2017 May 25;129(21):2847–56.

  13. Ville S, Le Bot S, Chapelet-Debout A, Blancho G,Fremeaux-Bacchi V, Deltombe C, et al. AtypicalHUS relapse triggered by COVID-19. Kidney Int.2021 Jan;99(1):267–8.

  14. Basak R, Wang X, Keane C, Woroniecki R.Atypical presentation of atypical haemolyticuraemic syndrome. BMJ Case Rep. 2018 Feb11;2018:bcr2017222560. Available at: https://doi.org/10.1136/bcr-2017-222560

  15. Valga F, Vega-Díaz N, Macía M, Monzón T,Rodríguez-Pérez JC. Targeting complement insevere coronavirus disease 2019 to addressmicrothrombosis. Clin Kidney J. 2020 Jun12;13(3):477–9.ID




2020     |     www.medigraphic.com